References
- McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the US. Cancer. 2005;103:1000–07. doi:https://doi.org/10.1002/cncr.20866.
- Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651–59. doi:https://doi.org/10.1167/iovs.03-0538.
- Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23:8076–80. doi:https://doi.org/10.1200/JCO.2005.02.6534.
- Collaborative Ocular Melanoma Study Group, Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005;123:1639–43. doi:https://doi.org/10.1001/archopht.123.12.1639.
- Agarwala SS, Eggermont AM, O’Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014;120:781–89. doi:https://doi.org/10.1002/cncr.28480.
- Rossi E, Schinzari G, Maiorano BA, Indellicati G, Di Stefani A, Pagliara MM, Fragomeni SM, De Luca EV, Sammarco MG, Garganese G, et al. Efficacy of immune checkpoint inhibitors in different types of melanoma. Hum Vaccin Immunother. 2020;1–10. doi:https://doi.org/10.1080/21645515.2020.1771986.
- Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest oncology group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol. 1998;21:568–72. doi:https://doi.org/10.1097/00000421-199812000-00008.
- Nathan F, Sato T, and Hart E. Response to combination chemotherapy of liver metastasis from choroidal melanoma compared with cutaneous melanoma (abstract). Proc Am Soc Clin Onc . 1994;13.
- Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS. Treatment of uveal melanoma metastatic to the liver; a review of the MD Anderson cancer center experience and prognostic factors. Cancer. 1995;76:1665–70. doi:https://doi.org/10.1002/1097-0142(19951101)76:9<1665::aid-cncr2820760925>3.0.co;2-j.
- Schinzari G, Rossi E, Cassano A, Dadduzio V, Quirino M, Pagliara M, Blasi MA, Barone C. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Melanoma Res. 2017;27:591–95. doi:https://doi.org/10.1097/CMR.0000000000000401.
- Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36:1232–39. doi:https://doi.org/10.1200/JCO.2017.74.1090.
- Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61(1):41–48. doi:https://doi.org/10.1007/s00262-011-1089-0.
- Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One. 2015;10:e0118564. doi:https://doi.org/10.1371/journal.pone.0118564.
- Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH. Clinical activity and safety of pembrolizumab in ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology. 2016;5:e1143997. doi:https://doi.org/10.1080/2162402X.2016.1143997.
- Algazi PA, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JP. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122:3344–53. doi:https://doi.org/10.1002/cncr.30258.
- Rossi E, Pagliara MM, Orteschi D, Dosa T, Sammarco MG, Caputo CG, Petrone G, Rindi G, Zollino M, Blasi MA, et al. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunol Immunother. 2019;68:1179–85. doi:https://doi.org/10.1007/s00262-019-02352-6.
- Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Alonso Carrión L, Martín-Algarra S, López Castro R, Curiel T, Rodríguez-Abreu D, Redrado M, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39:586–98. doi:https://doi.org/10.1200/JCO.20.00550.
- Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS, Harbour JW. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 2020;11:496. doi:https://doi.org/10.1038/s41467-019-14256-1.
- Niederkorn JY. Immune escape mechanisms of intraocular tumors. Progr Retin Eye Res. 2009;28:329–47. doi:https://doi.org/10.1016/j.preteyeres.2009.06.002.
- Terai M, Londin E, Rochani A, Link E, Lam B, Kaushal G, Bhushan A, Orloff M, Sato T. Expression of tryptophan 2,3-Dioxygenase in metastatic uveal melanoma. Cancers (Basel). 2020;12:405. doi:https://doi.org/10.3390/cancers12020405.
- Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14:996–1006. doi:https://doi.org/10.1038/ni.2691.
- Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013;3:1122–29. doi:https://doi.org/10.1158/2159-8290.CD-13-0330.
- Rodrigues M, Mobuchon L, Houy A, Fiévet A, Gardrat S, Barnhill RL, Popova T, Servois V, Rampanou A, Mouton A, et al. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nat. Commun. 2018;9:1866. doi:https://doi.org/10.1038/s41467-018-04322-5.
- Rossi E, Schinzari G, Zizzari IG, Maiorano BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A, Rindi G, et al. Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? Cancers (Basel). 2019;11:1055. doi:https://doi.org/10.3390/cancers11081055.
- Zizzari IG, Napoletano C, Di Filippo A, Botticelli A, Gelibter A, Calabrò F, Rossi E, Schinzari G, Urbano F, Pomati G, et al. Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma. Cancers (Basel). 2020;12:2620. doi:https://doi.org/10.3390/cancers12092620.
- Zizzari IG, Di Filippo A, Scirocchi F, Di Pietro FR, Rahimi H, Ugolini A, Scagnoli S, Vernocchi P, Del Chierico F, Putignani L, et al. Soluble immune checkpoints, gut metabolites and performance status as parameters of response to nivolumab treatment in NSCLC patients. J Pers Med. 2020;10:208. doi:https://doi.org/10.3390/jpm10040208.
- Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020;20:209–15. doi:https://doi.org/10.1038/s41577-019-0264-y.
- Gu D, Ao X, Yang Y, Chen Z, Xu X. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer. 2018;6:132. doi:https://doi.org/10.1186/s40425-018-0449-0.
- Machiraju D, Wiecken M, Lang N, Hülsmeyer I, Roth J, Schank TE, Eurich R, Halama N, Enk A, Hassel JC. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. Oncoimmunology. 2021 May 25;10(1):1926762. doi:https://doi.org/10.1080/2162402X.2021.1926762.
- Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving Anti-PD-1-based immunotherapy. Clin Cancer Res. 2019;25:1557–63. doi:https://doi.org/10.1158/1078-0432.CCR-18-2795.
- Bakouny Z, Choueiri TK. IL-8 and cancer prognosis on immunotherapy. Nat Med. 2020 May;26:650–51. doi:https://doi.org/10.1038/s41591-020-0873-9.
- Tagliaferri L, Lancellotta V, Fionda B, Mangoni M, Casà C, Di Stefani A, Pagliara MM, D’Aviero A, Schinzari G, Chiesa S, et al. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother. 2021:1–8. doi:https://doi.org/10.1080/21645515.2021.1903827.
- Luu K, Shao Z, Schwarz H. The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention. J Leukoc Biol. 2020;107:731–38. doi:https://doi.org/10.1002/JLB.2MR1119-224R.
- Hebbar M, Jeannin P, Magistrelli G, Hatron PY, Hachulla E, Devulder B, Bonnefoy JY, Delneste Y. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren’s syndrome and systemic sclerosis. Clin Exp Immunol. 2004;136:388–92. doi:https://doi.org/10.1111/j.1365-2249.2004.02427.x.
- Lutzky J, Feun LG, Magallanes N, Kwon D, Harbour JW. NCT04552223: a phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094). Abs TPS9590 2021 ASCO Annual Meeting. Vol. JCO 30, 15 suppl. doi: https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS9590
- Lunardi S, Lim SY, Muschel RJ, Brunner TB. IP-10/CXCL10 attracts regulatory T cells: implication for pancreatic cancer. Oncoimmunology. 2015;4:e1027473. doi:https://doi.org/10.1080/2162402X.2015.1027473.
- Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72. doi:https://doi.org/10.1038/nri.2017.49.
- Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today. 1999;20:469–73. doi:https://doi.org/10.1016/s0167-5699(99)01520-0.
- Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189:1363–72. doi:https://doi.org/10.1084/jem.189.9.1363.
- Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000;164:3596–99. doi:https://doi.org/10.4049/jimmunol.164.7.3596.
- Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V, Bonanno G, Rutella S, Durelli I, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2007;109:2871–77. doi:https://doi.org/10.1182/blood-2006-07-036863.
- Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008;181:5396–404. doi:https://doi.org/10.4049/jimmunol.181.8.5396.
- Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH, Young JW. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood. 2009;114:555–63. doi:https://doi.org/10.1182/blood-2008-11-191197.
- Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 2018;16:219. doi:https://doi.org/10.1186/s12967-018-1595-3.
- Botticelli A, Mezi S, Pomati G, Cerbelli B, Cerbelli E, Roberto M, Giusti R, Cortellini A, Lionetto L, Scagnoli S, et al. Tryptophan catabolism as immune mechanism of primary resistance to anti-PD-1. Front Immunol. 2020;11:1243. doi:https://doi.org/10.3389/fimmu.2020.01243.
- Jones A, Bourque J, Kuehm L, Opejin A, Teague RM, Gross C, Hawiger D. Immunomodulatory functions of BTLA and HVEM govern induction of extrathymic regulatory T cells and tolerance by dendritic cells. Immunity. 2016;45:1066–77. doi:https://doi.org/10.1016/j.immuni.2016.10.008.
- Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE 3rd, Koeppen H, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020;26:693–98. doi:https://doi.org/10.1038/s41591-020-0860-1.
- Li Y, Yang S, Li Z, Meng H, Jin W, Yang H, Yin W. Soluble glucocorticoid-induced tumor necrosis factor receptor regulates Helios expression in myasthenia gravis. J Transl Med. 2019;17:168. doi:https://doi.org/10.1186/s12967-019-1916-1.
- McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A. 1995;92:8059–63. doi:https://doi.org/10.1073/pnas.92.17.8059.
- Sugiura D, Maruhashi T, Okazaki IM, Shimizu K, Maeda TK, Takemoto T, Okazaki T. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019;364:558–66. doi:https://doi.org/10.1126/science.aav7062.